Davis Investment Partners LLC Purchases 6,770 Shares of Johnson & Johnson $JNJ

Davis Investment Partners LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 31.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,288 shares of the company’s stock after purchasing an additional 6,770 shares during the period. Johnson & Johnson makes up approximately 1.8% of Davis Investment Partners LLC’s holdings, making the stock its 12th largest holding. Davis Investment Partners LLC’s holdings in Johnson & Johnson were worth $5,263,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the third quarter worth approximately $28,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $27,000. Semmax Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $35,000. Finally, Signature Resources Capital Management LLC grew its holdings in shares of Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on JNJ. Raymond James Financial upped their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Guggenheim increased their target price on Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a report on Friday, December 5th. Scotiabank assumed coverage on Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target on the stock. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Finally, Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $211.25.

Johnson & Johnson Trading Up 0.1%

NYSE JNJ opened at $207.26 on Friday. The stock has a market cap of $499.35 billion, a P/E ratio of 20.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18. The stock has a 50 day simple moving average of $201.17 and a two-hundred day simple moving average of $182.64. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.